• No results found

Prognosis in monoclonal proteinaemia Schaar, C.G.

N/A
N/A
Info
Downloaden
Protected

Academic year: 2021

Share "Prognosis in monoclonal proteinaemia Schaar, C.G."

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Download het nu ( 3 pagina )

Hele tekst

(1)

Prognosis in monoclonal proteinaemia

Schaar, C.G.

Citation

Schaar, C. G. (2006, November 9). Prognosis in monoclonal

proteinaemia. Retrieved from https://hdl.handle.net/1887/4983

Version:

Corrected Publisher’s Version

License:

Licence agreement concerning inclusion of

doctoral thesis in the Institutional Repository of

the University of Leiden

Downloaded from:

https://hdl.handle.net/1887/4983

(2)

List of abbreviations

β2M Beta-2-microglobulin

CCCW Comprehensive Cancer Centre West (Integraal Kanker Centrum West; IKW) CRP C-reactive protein

HOVON Hematologie Oncologie Volwassenen Nederland IFN-alpha Interferon-alpha

IL-6 Interleukin-6

IMWG International Myeloma Working Group

MM Multiple Myeloma, also known as ‘Kahler’s disease’ or ‘Rustizky’s disease’

M-protein(aemia) Monoclonal Protein(aemia)

MGUS Monoclonal Gammopathy of Unknown Significance MP Melphalan-Prednisone chemotherapy

NCAM Neural Cell Adhesion Molecule NHL Non Hodgkin’s lymphoma OS Overall survival

Paraprotein(aemia) Former name for M-protein(aemia) PFS Progression-free survival

QoL Quality of life

SMR Standardized Mortality Ratio WHO World Health Organisation

141

(3)

142

Referenties

Download het nu ( PDF - 3 pagina - 113.18 KB )

GERELATEERDE DOCUMENTEN

Prognosis in monoclonal proteinaemia Schaar, C.G.

In a previous study, using our database that also included a large number of patients with multiple myeloma, we devised a Myeloma Risk Score using the M-protein serum level and

Prognosis in monoclonal proteinaemia Schaar, C.G.

Therefore, the relation between survival and the rate of monoclonal protein (M-protein) decrement during the first cycles of therapy was prospectively assessed in 262 patients

Prognosis in monoclonal proteinaemia Schaar, C.G.

Background: The effect of interferon- α 2b (IFN-α) on progression free and overall survival as well as quality of life was studied in mainly elderly patients with multiple myeloma

Prognosis in monoclonal proteinaemia Schaar, C.G.

Not surprisingly, survival was also influenced by the M-protein related internal diagnosis especially MGUS associated with a solid tumour (median 0.4 (95% CI 0.2-0.5) years) compared

Prognosis in monoclonal proteinaemia Schaar, C.G.

Serum IL-6 spiegels werden bepaald in 212 duidelijk omschreven patiënten met M- proteïnemie: multipel myeloom (60), andere hematologische ziekten (46), solide tumoren

Prognosis in monoclonal proteinaemia Schaar, C.G.

The population-based Paraprotein database was established at the Comprehensive Cancer Centre West (CCCW, Integraal Kankercentrum West) in cooperation with the physicians

Prognosis in monoclonal proteinaemia Schaar, C.G.

Hierna was hij negen maanden werkzaam als arts-assistent niet in opleiding op de afdeling Interne Geneeskunde van het Bronovo Ziekenhuis te Den Haag, alwaar per 1 januari 1993

Prognosis in monoclonal proteinaemia Schaar, C.G.

Serum interleukin-6 has no discriminatory role in para- proteinaemia nor a prognostic role in multiple myeloma.. Ong F, Hermans J, Noordijk EM, Schaar CG,